Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 1 (1) |
| Completed vs Stopped Early | 27 / 1 (3.5%) |
| Median Closed Actual Enrollment | 95 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Mayo Clinic Rochester | Rochester, MN | 2 |
| Emory Winship Cancer Institute | Atlanta, GA | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05392192 | A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Aldeyra Therapeutics Interactive Dossier, benchmark peers in Ophthalmology and Sensory, or review the Healthcare Price & Patent Cliff Crosswalk.